Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 7.4
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Data is available to registered users only
Target Price
Buy
Sell